ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
“ImmunoGen has in-depth expertise in all aspects of ADCs, which has
resulted in the most comprehensive toolbox of ADC technologies in the
Details of ImmunoGen’s poster presentations are as follows:
Title: “A new class of DNA alkylating indolino-benzodiazepine
agents (BIAs) linked with a DNA binding moiety for use with
antibody-drug conjugates (ADCs)” (abstract
Time: 1:00 –
- A new class of DNA alkylating effector molecules for use in ADC development in which an IGN (indolino-benzodiazepine) monomer subunit is connected to a DNA binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA ADCs displayed potent, antigen-specific in vitro activity across a panel of FRα-expressing cell lines. In vivo, these ADCs demonstrated potent efficacy in xenograft models at doses well below the maximum tolerated dose.
Title: “Development of an in vivo model system to assess the
interplay between the various drivers of antibody drug conjugate (ADC)
Time: 1:00 –
- To better understand the variables that impact ADC pharmacokinetics, tolerability, bio-distribution, and efficacy, a novel, cross-reactive model system was created. An anti-murine folate receptor alpha (FRα) antibody was generated that binds to both mouse and human FRα. The model system allows experiments to be designed in a cross-reactive system to examine how modifications to the antibody, linker or cytotoxic payload impact safety, and efficacy.
Title: “Evaluation of endoglin/CD105 as a tumor vasculature
target with antibody drug conjugates” (abstract
Time: 1:00 –
- Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. It was evaluated as an oncology target using ADCs of an anti-CD105 antibody with potent anti-microtubule maytansinoids DM1 and DM4, and the highly potent IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM and huRH105-DGN549 conjugates produced modest anti-tumor activity and therapeutic indices in rat models.
Additional information and full abstracts can be found at www.aacr.org.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with
Kadcyla® is a registered trademark of Genentech, a member of
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.
Sarah Kiely, 781-895-0600
Courtney O’Konek, 781-895-0600
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657